Author

van Roon EN

Unknown affiliation - Cited by 3,644

Biography

Dr. van Roon EN is a Professor in the Faculty of Science and Engineering at the University of Groningen, Netherlands. His research interests include the Intensive Care Unit and Drug Development.
Title
Cited by
Year
Prediction of response to biological treatment with monoclonal antibodies in severe asthma
JA Kroes, SW Zielhuis, EN Van Roon, A Ten BrinkeBiochemical pharmacology 179, 113978, 2020202
42
2020
Postoperative urinary retention: risk factors, bladder filling rate and time to catheterization: an observational study as part of a randomized controlled trial
TA Brouwer, EN van Roon, PFWM Rosier, CJ Kalkman, N VeegerPerioperative Medicine 10 (1), 1-11, 2021202
19
2021
Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study
J Rozema, M Hoogendoorn, R Kibbelaar, E van den Berg, N Veeger, ...Blood advances 5 (5), 1344-1351, 2021202
10
2021
Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder
M Simoons, H Mulder, JTY Appeldoorn, AJ Risselada, AH Schene, ...Psychiatric genetics 30 (1), 19-29, 2020202
10
2020
High prevalence of peripheral neuropathy in multiple myeloma patients and the impact of vitamin D levels, a cross-sectional study
BE Oortgiesen, JA Kroes, P Scholtens, J Hoogland, ...Supportive Care in Cancer 30, 271-278, 2022202
9
2022
Optimizing omalizumab dosing in severe asthma—the exploration of therapeutic drug monitoring
JA Kroes, SW Zielhuis, AN Van der Meer, K De Jong, EN Van Roon, ...The Journal of Allergy and Clinical Immunology: In Practice (3), 1408-1410. e1, 2021202
9
2021
Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: a population‐based study
J Rozema, EN van Roon, RE Kibbelaar, NJGM Veeger, CL Slim, H de Wit, ...Transfusion 61 (10), 2877-2884, 2021202
5
2021
Reasons for discontinuation of novel oral anticoagulant therapy in patients with atrial fibrillation
D Mitrovic, R Folkeringa, N Veeger, E van RoonCurrent Medical Research and Opinion 36 (4), 47-3, 2020202
5
2020
Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report
JA Kroes, SW Zielhuis, C Bethlehem, A Ten Brinke, EN Van RoonEuropean Journal of Hospital Pharmacy 29 (), 235-236, 2022202
4
2022
The quality of instructional YouTube videos for the administration of intranasal spray: observational study
MM Peters-Geven, C Rollema, EI Metting, EN van Roon, TW de VriesJMIR Medical Education 6 (2), e23668, 2020202
4
2020
A clinical effect of disease-modifying treatment on alloimmunisation in transfused patients with myelodysplastic syndromes: data from a population-based study
J Rozema, CL Slim, NJGM Veeger, RE Kibbelaar, H de Wit, EN van Roon, ...Blood Transfusion 20 (1), 18, 2022202
4
2022
Applicability of somatic monitoring instructions in clinical practice guidelines on antipsychotic drug use
JMJL Brouwer, E Olde Hengel, AJ Risselada, EN van Roon, H MulderBMC psychiatry 21 (1), 1-8, 2021202
4
2021
Cumulative corticosteroid-sparing effect of anti-interleukin-5/5Ra in eosinophilic asthma
JA Kroes, SWJ Zielhuis, K De Jong, S Hashimoto, JK Sont, SW Zielhuis, ...European Respiratory Journal 60 (5), 2022202
4
2022
Urea for hyponatraemia due to the syndrome of inappropriate antidiuretic hormone secretion
J Woudstra, MP De Boer, L Hempenius, EN Van RoonNeth. J. Med 78 (3), 125-132, 2020202
4
2020
Observational study of administering intranasal steroid sprays by healthcare workers
M de Boer, C Rollema, E van Roon, T de VriesBMJ open 10 (8), e037660, 2020202
4
2020
Effect of Roux-en-Y gastric bypass on the bioavailability of metoprolol from immediate and controlled release tablets: a single oral dose study before and after surgery
JP Yska, JTM Wanders, B Odigie, JA Apers, M Emous, ERE Totté, ...European Journal of Hospital Pharmacy 27 (e1), e19-e24, 2020202
3
2020
Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis
Bone mineral density improves during years of treatment with bisphosphonates in patients with ankylosing spondylitisS Arends, F Wink, J Veneberg, R Bos, E van Roon, E van der Veer, ...British Journal of Clinical Pharmacology 87 (), 644-651, 010
2
2021
No decrease in fracture risk despite 15 years of treatment evolution for multiple myeloma patients: A Danish nationwide case-control study
BE Oortgiesen, JHM Driessen, M Hoogendoorn, RE Kibbelaar, ...Bone 134, 11599, 000
2
2020
Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes
J Rozema, M Hoogendoorn, I Potma, I Ten Seldam, NJGM Veeger, ...EJHaem 3 (3), 775-784, 0
2
2022
Adverse drug reactions of intranasal corticosteroids in the netherlands: an analysis from the Netherlands Pharmacovigilance Center
C Rollema, EN van Roon, C Ekhart, FPAM van Hunsel, TW de VriesDrugs-Real World Outcomes 9 (3), 31-331, 0
2
2022

Referred From: https://scholar.google.com/citations?user=XfM7nhEAAAAJ&hl=en

Cited by
Citations 3644
h-index 33
i10-index 63
Recommended Journals
Open Access Journals